M2GEN applauds President Biden’s Cancer Moonshot program and supports his vision to reduce cancer death rates by 50% over the next 25 years. We pledge to continue working towards our shared mission of accelerating the rate of progress we collectively make in the fight to prevent and cure all cancers.
For over 15 years, M2GEN has been dedicated to powering the answers to the toughest questions in cancer through our ORIEN® partners. By connecting patients, providers, and researchers, we are fundamentally changing the way cancer is studied and treated. President Biden’s bold vision to end cancer as we know it illustrates the power of collaboration to advance cutting edge research through the pipeline to patients and communities.
Since 2006, M2GEN has been disrupting the way industry researchers discover new cancer therapies while developing the necessary tools to drive the creation of innovative and novel precision cancer medicines. In alignment with the Cancer Moonshot initiative, M2GEN’s Total Cancer Care protocol, Oncology Research Information Exchange Network® (ORIEN®), and AVATAR data product allow researchers to track patient clinical progressions over their lifetime, providing the richest data source available for targeted cancer treatments and therapy advancement.
At M2GEN, we believe in a world where more patients are connected to a cure. Accelerating the discovery and delivery of precision medicine will provide better outcomes for present and future patients. We are excited to continue our groundbreaking work in support of the Biden Administration and our government leaders to advance cancer research and treatments together.
M2GEN is committed to breaking down research silos and bringing together leaders in oncology in order to improve outcomes and quality of life for cancer patients around the globe. If you’d like to know more about M2GEN, ORIEN, or any of our other products or services, contact us today.